Hypomagnesemia is a common entity occurring in up to 12 percent of hospitalized patients . The incidence rises to as high as 60 to 65 percent in patients in an. Asystole is a cardiac arrest rhythm in which there is no discernible electrical activity on the ECG monitor. Asystole is sometimes referred to as a “flat line.”. Read medical definition of Hypokalemia. Hypokalemia: Low blood potassium. Potassium is the major positive ion (cation) found inside of cells. What are the possible side effects of hydrochlorothiazide and spironolactone (Aldactazide)? Get emergency medical help if you have any of these signs of an allergic. Please check the synonyms listing to find the. Following a myocardial infarction, a client develops an arrhythmia and requires a continuous infusion of lidocaine. To monitor the effectiveness of the intervention. Approach Considerations, Initial Emergency Management, Pharmacologic Therapy and Dialysis. Murata K, Baumann NA, Saenger AK, Larson TS, Rule AD, Lieske JC. Relative performance of the MDRD and CKD- EPI equations for estimating glomerular filtration rate among patients with varied clinical presentations. Clin J Am Soc Nephrol. Electrocardiographic manifestations: electrolyte abnormalities. J Emerg Med. Chew HC, Lim SH. Electrocardiographical case. A tale of tall T's. Hyperkalaemia. Singapore Med J. San- Cristobal P, de los Heros P, Ponce- Coria J, et al. WNK kinases, renal ion transport and hypertension. Am J Nephrol. 2. 8(5): 8. Shaffer SG, Kilbride HW, Hayen LK, Meade VM, Warady BA. Hyperkalemia in very low birth weight infants. Extreme hyperkalemia. South Med J. 9. 8(7): 7. Kahle KT, Ring AM, Lifton RP. Molecular physiology of the WNK kinases. Annu Rev Physiol. Huang CL, Kuo E. Mechanisms of disease: WNK- ing at the mechanism of salt- sensitive hypertension. Nat Clin Pract Nephrol. Hoorn EJ, Nelson JH, Mc. Cormick JA, Ellison DH. The WNK kinase network regulating sodium, potassium, and blood pressure. J Am Soc Nephrol. Hadchouel J, Ellison DH, Gamba G. Regulation of Renal Electrolyte Transport by WNK and SPAK- OSR1 Kinases. Annu Rev Physiol. The ICU Book. Baltimore: Williams & Wilkins; 1. Preston RA, Afshartous D, Rodco R, Alonso AB, Garg D. Evidence for a gastrointestinal- renal kaliuretic signaling axis in humans. Gumz ML, Rabinowitz L, Wingo CS. An Integrated View of Potassium Homeostasis. N Engl J Med. 3. 73 (1): 6. Bhananker SM, Ramamoorthy C, Geiduschek JM, Posner KL, Domino KB, Haberkern CM, et al. Anesthesia- related cardiac arrest in children: update from the Pediatric Perioperative Cardiac Arrest Registry. Anesth Analg. 1. 05(2): 3. Einhorn LM, Zhan M, Hsu VD, Walker LD, Moen MF, Seliger SL, et al. The frequency of hyperkalemia and its significance in chronic kidney disease. Arch Intern Med. 2. Jun 2. 2. 1. 69(1. Diabetes and Drug- Associated Hyperkalemia: Effect of Potassium Monitoring. J Gen Intern Med. Jan 2. 0. Predicting the risk of hyperkalemia in patients with chronic kidney disease starting lisinopril. Pharmacoepidemiol Drug Saf. Lin HH, Yang YF, Chang JK, et al. Renin- angiotensin system blockade is not associated with hyperkalemia in chronic hemodialysis patients. Weir MR, Rolfe M. Potassium homeostasis and Renin- Angiotensin- aldosterone system inhibitors. Clin J Am Soc Nephrol. Preston RA, Afshartous D, Garg D, et al. Mechanisms of impaired potassium handling with dual renin- angiotensin- aldosterone blockade in chronic kidney disease. Hypertension. 2. 00. Mar 2. 3. Khanna A, White WB. The management of hyperkalemia in patients with cardiovascular disease. Schweiger B, Moriarty MW, Cadnapaphornchai MA. Case report: severe neonatal hyperkalemia due to pseudohypoaldosteronism type 1. Curr Opin Pediatr. Papaioannou V, Dragoumanis C, Theodorou V, Pneumatikos I. The propofol infusion 'syndrome' in intensive care unit: from pathophysiology to prophylaxis and treatment. Acta Anaesthesiol Belg. Matthews JM. Succinylcholine- induced hyperkalemia. Anesthesiology. 1. Piotrowski AJ, Fendler WM. Hyperkalemia and cardiac arrest following succinylcholine administration in a 1. Pediatr Crit Care Med. Gronert GA, Theye RA. Pathophysiology of hyperkalemia induced by succinylcholine. Anesthesiology. 4. Acute hyperkalemia associated with intravenous epsilon- aminocaproic acid therapy. Am J Kidney Dis. 3. Carroll HJ, Tice DA. The effects of epsilon amino- caproic acid upon potassium metabolism in the dog. Mattu A, Brady WJ, Robinson DA. Electrocardiographic manifestations of hyperkalemia. Am J Emerg Med. 1. Actas Dermosifiliogr. Pavlakovic H, Kietz S, Lauerer P, Zutt M, Lakomek M. Hyperkalemia complicating propranolol treatment of an infantile hemangioma. Cummings CC, Mc. Ivor ME. Fluoride- induced hyperkalemia: the role of Ca. K+ channels. Am J Emerg Med. Suzuki H, Terai M, Hamada H, Honda T, Suenaga T, Takeuchi T, et al. Cyclosporin A treatment for Kawasaki disease refractory to initial and additional intravenous immunoglobulin. Pediatr Infect Dis J. Nowicki TS, Bjornard K, Kudlowitz D, Sandoval C, Jayabose S. Early recognition of renal toxicity of high- dose methotrexate therapy: a case report. J Pediatr Hematol Oncol. Gowda RM, Cohen RA, Khan IA. Toad venom poisoning: resemblance to digoxin toxicity and therapeutic implications. Inborn errors of adrenal steroidogenesis. Mol Cell Endocrinol. Aldosterone synthase deficiency and related disorders. Mol Cell Endocrinol. Sartorato P, Khaldi Y, Lapeyraque AL, et al. Inactivating mutations of the mineralocorticoid receptor in Type I pseudohypoaldosteronism. Mol Cell Endocrinol. Mar 3. 1. 2. 17(1- 2): 1. Geller DS, Rodriguez- Soriano J, Vallo Boado A, Schifter S, Bayer M, Chang SS, et al. Mutations in the mineralocorticoid receptor gene cause autosomal dominant pseudohypoaldosteronism type I. Role of WNK kinases in regulating tubular salt and potassium transport and in the development of hypertension. Am J Physiol Renal Physiol. F2. 45- 5. 2. Mutations in kelch- like 3 and cullin 3 cause hypertension and electrolyte abnormalities. Jan 2. 2. 4. 82(7. Autosomal recessive hyponatremia due to isolated salt wasting in sweat associated with a mutation in the active site of Carbonic Anhydrase 1. Jurkat- Rott K, Mitrovic N, Hang C, Kouzmekine A, Iaizzo P, Herzog J, et al. Voltage- sensor sodium channel mutations cause hypokalemic periodic paralysis type 2 by enhanced inactivation and reduced current. Proc Natl Acad Sci U S A. Aug 1. 5. 9. 7(1. Potassium metabolism in extremely low birth weight infants in the first week of life. Pt 1): 8. 1- 6. Jarman PR, Kehely AM, Mather HM. Hyperkalaemia in diabetes: prevalence and associations. Postgrad Med J. 7. Hyperkalemia in outpatients using angiotensin- converting enzyme inhibitors. How much should we worry? Arch Intern Med. 1. Jan 1. 2. 1. 58(1): 2. Effect of aliskiren on post- discharge outcomes among diabetic and non- diabetic patients hospitalized for heart failure: insights from the ASTRONAUT trial. Eur Heart J. 3. 4(4. Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial. Mar 2. 0. 3. 09(1. Mann JF, Anderson C, Gao P, Gerstein HC, Boehm M, Ryd. Dual inhibition of the renin- angiotensin system in high- risk diabetes and risk for stroke and other outcomes: results of the ONTARGET trial. J Hypertens. 3. 1(2): 4. Juurlink DN, Mamdani MM, Lee DS. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med. 3. 51: 5. Hyperkalaemia in patients in hospital. Br Med J (Clin Res Ed). Malignant hyperthermia and muscular dystrophies. Anesth Analg. 1. 09(4): 1. Segura J, Ruilope LM. Hyperkalemia risk and treatment of heart failure. Heart Fail Clin. 4(4): 4. Weisberg LS. Management of severe hyperkalemia. Crit Care Med. 3. Hughes- Austin JM, Rifkin DE, Beben T, Katz R, Sarnak MJ, Deo R, et al. The Relation of Serum Potassium Concentration with Cardiovascular Events and Mortality in Community- Living Individuals. Clin J Am Soc Nephrol. Braden GL, O'Shea MH, Mulhern JG, et al. Acute renal failure and hyperkalaemia associated with cyclooxygenase- 2 inhibitors. Nephrol Dial Transplant. Life- threatening hyperkalemia during combined therapy with angiotensin- converting enzyme inhibitors and spironolactone: an analysis of 2. Apr 1. 5. 1. 10(6): 4. Zietse R, Zoutendijk R, Hoorn EJ. Fluid, electrolyte and acid- base disorders associated with antibiotic therapy. Nat Rev Nephrol. 5(4): 1. Kamel KS, Halperin ML. Intrarenal urea recycling leads to a higher rate of renal excretion of potassium: an hypothesis with clinical implications. Curr Opin Nephrol Hypertens. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1. Mar 1. 6. 1. 30(6): 4. Watson M, Abbott KC, Yuan CM. Damned if you do, damned if you don't: potassium binding resins in hyperkalemia. Clin J Am Soc Nephrol. Treatment of Acute Hyperkalaemia in Adults. The Renal Association. Available at http: //www. Xc. D0. IG3. Qqd. B4c. 5G. dpbs. March 1, 2. Accessed: October 6, 2. Elliott MJ, Ronksley PE, Clase CM, Ahmed SB, Hemmelgarn BR. Management of patients with acute hyperkalemia. Oct 1. 9. 1. 82 (1. Ion- exchange resins for the treatment of hyperkalemia: are they safe and effective? J Am Soc Nephrol. Pierce DA, Russell G, Pirkle JL Jr. The Incidence of Hypoglycemia in Patients With Low e. GFR Treated With Insulin and Dextrose for Hyperkalemia. Ann Pharmacother. Sep 2. 8. Dick TB, Raines AA, Stinson JB, Collingridge DS, Harmston GE. Fludrocortisone is effective in the management of tacrolimus- induced hyperkalemia in liver transplant recipients. Transplant Proc. 4. Rogers FB, Li SC. Acute colonic necrosis associated with sodium polystyrene sulfonate (Kayexalate) enemas in a critically ill patient: case report and review of the literature. Mc. Gowan CE, Saha S, Chu G, Resnick MB, Moss SF. Intestinal necrosis due to sodium polystyrene sulfonate (Kayexalate) in sorbitol. South Med J. 1. 02(5): 4. Safety: Kayexalate (sodium polystyrene sulfonate) powder. Available at http: //www. Safety/Med. Watch/Safety. Information/ucm. 18. Accessed: October 5, 2. Harel Z, Harel S, Shah PS, Wald R, Perl J, Bell CM. Gastrointestinal adverse events with sodium polystyrene sulfonate (Kayexalate) use: a systematic review. Bakris GL, Pitt B, Weir MR, Freeman MW, Mayo MR, Garza D, et al. Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney Disease: The AMETHYST- DN Randomized Clinical Trial. Jul 1. 4. 3. 14 (2): 1. Pitt B, Bakris GL, Bushinsky DA, Garza D, Mayo MR, Stasiv Y, et al. Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors. Eur J Heart Fail. Khedr E, Abdelwhab S, El- Sharkay M, et al.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. Archives
November 2017
Categories |